Market Overview

UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform

Related GEVA
Can The Rally In Synageva Biopharma Shares Continue?
Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa

Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.

Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."

GEVA closed at $38.50 on Friday.

Latest Ratings for GEVA

DateFirmActionFromTo
Oct 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014CitigroupInitiates Coverage onNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters